AbbVie

Yahoo Finance • 13 hours ago

This Biotech Stock Soars 36%. Pancreatic Cancer Trial Was a Success.

Revolution Medicines announces positive Phase 3 clinical trial results for its pancreatic cancer treatment. Continue Reading... Full story

Yahoo Finance • 17 hours ago

CollPlant Issues Letter to Shareholders

REHOVOT, Israel, April 13, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human collagen (rhCo... Full story

Yahoo Finance • 18 hours ago

Antibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 Drugs

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The competitive landscape report offers extensive analysis of over 180 compani... Full story

Yahoo Finance • 21 hours ago

AbbVie signs pain drug licensing deal with China’s Haisco

[Abbvie] vzphotos/iStock Editorial via Getty Images * AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]) has signed an exclusive licensing agreement with China-based Haisco Pharmaceutical Group to advance the global development of nov... Full story

Yahoo Finance • 22 hours ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical... Full story

Yahoo Finance • 2 days ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Results from the Phase 2 IMGN853-0420 trial show an objective response rate of 62.7% and consistent safety findings with mirvetuximab soravtansine-gynx (ELAHERE®) plus carboplatin followed by a continuation of mirvetuximab soravtansine mon... Full story

Yahoo Finance • 3 days ago

AbbVie’s 340B Lawsuit Puts Drug Discounts And Margins Under The Microscope

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AbbVie has filed a legal challenge seeking to narrow and clarify w... Full story

Yahoo Finance • 3 days ago

Is It Too Late To Consider AbbVie (ABBV) After The Recent Share Price Pullback?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. If you are wondering whether AbbVie at around US$207.94 is still offering value or starting to l... Full story

Yahoo Finance • 3 days ago

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Friday afternoon, with the NYSE Health Care Index falling 1.1% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 days ago

3 Market-Beating Stocks with Competitive Advantages

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your... Full story

Yahoo Finance • 3 days ago

Catalyst Watch: Earnings heat up, Fedspeak flurry, and eyes on space

[Wall street and Broadway road sign in New York City] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MON... Full story

Yahoo Finance • 4 days ago

AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says

AbbVie (ABBV) is expected to report first-quarter earnings within its guidance range, but that may n PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 days ago

Dividend Roundup: AGNC Investments, Abbott Labs, AbbVie, and more

[Woman putting savings in a white piggy bank.] Guido Mieth This week's dividend activity included increased payouts from Agree Realty (ADC [https://seekingalpha.com/symbol/ADC]) as well as declarations from companies such as AGNC Investme... Full story

Yahoo Finance • 4 days ago

Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline

Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering. This report covers the seven major markets (7MM:... Full story

Yahoo Finance • 4 days ago

Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead

AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Cheap Dividend Stocks to Buy.Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead On April 8, Cantor Fitzgerald lowered its price recommendation on AbbVie Inc... Full story

Yahoo Finance • 5 days ago

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

Large-cap and small- to medium-cap biopharmaceutical companies in BofA Securities' coverage are not PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 5 days ago

This Investor's $5 Million ETF Buy Pushes 2028 Bond Fund to Nearly 4% of AUM

Red Spruce Capital disclosed a buy of 235,496 additional shares of Invesco BulletShares 2028 Corporate Bond ETF(NASDAQ:BSCS), with an estimated trade value of $4.84 million based on quarterly average pricing, according to an SEC filing dat... Full story

Yahoo Finance • 5 days ago

1 Healthcare Stock on Our Watchlist and 2 We Avoid

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s... Full story

Yahoo Finance • 5 days ago

Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%

Amneal Pharmaceuticals LLC Important ophthalmic treatment expected to be an important growth driver for Amneal’s Affordable Medicines segment BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or... Full story

Yahoo Finance • 5 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 1.6% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story